SPR1020

SPR1020 is a next-generation, highly selective small molecule inhibitor of Poly (ADP-ribose) polymerase 1 (PARP1), developed by Shanghai SciBrunch Therapeutics. Unlike first-generation pan-PARP inhibitors such as olaparib, SPR1020 specifically targets PARP1 while sparing PARP2, a strategy designed to minimize hematological toxicities associated with PARP2 inhibition. It operates through the principle of synthetic lethality, particularly in tumors with BRCA mutations or other homologous recombination repair (HRR) pathway deficiencies. Notably, SPR1020 is designed to penetrate the blood-brain barrier, offering potential efficacy against brain metastases. It is currently being evaluated in Phase I/II clinical trials for various advanced solid tumors, including breast, ovarian, prostate, and pancreatic cancers.